Key Points
- Director purchase: Evommune Director Robert Lorne Hopfner bought 1,000 shares at $17.35 on Dec. 19 for $17,350, increasing his stake to 4,026 shares (a 33.05% rise) per an SEC filing.
- Earnings miss: The company reported Q4 EPS of ($8.07) versus consensus ($6.58) while revenue matched expectations at $10.0 million, underscoring continued losses.
- Analyst optimism: Multiple firms initiated or upgraded coverage (ratings from Hold to Strong Buy), leaving an average analyst rating of "Buy" and an average price target of $39.33 versus the current ~ $17 share price (1‑yr range $13.89–$24.03).
Evommune, Inc. (NYSE:EVMN - Get Free Report) Director Robert Lorne Hopfner acquired 1,000 shares of the firm's stock in a transaction dated Friday, December 19th. The shares were purchased at an average cost of $17.35 per share, for a total transaction of $17,350.00. Following the acquisition, the director directly owned 4,026 shares in the company, valued at $69,851.10. This represents a 33.05% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Evommune Price Performance
EVMN opened at $17.00 on Tuesday. Evommune, Inc. has a 1 year low of $13.89 and a 1 year high of $24.03.
Evommune (NYSE:EVMN - Get Free Report) last posted its quarterly earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share for the quarter, missing analysts' consensus estimates of ($6.58) by ($1.49). The business had revenue of $10.00 million for the quarter, compared to analysts' expectations of $10.00 million.
Analysts Set New Price Targets
Several research firms recently issued reports on EVMN. Evercore ISI initiated coverage on shares of Evommune in a research report on Monday, December 1st. They issued an "outperform" rating and a $40.00 price target for the company. Wall Street Zen upgraded Evommune from a "sell" rating to a "hold" rating in a research note on Sunday, December 14th. Leerink Partners initiated coverage on Evommune in a research report on Monday, December 1st. They set an "outperform" rating and a $42.00 target price for the company. Leerink Partnrs raised Evommune to a "strong-buy" rating in a research note on Monday, December 1st. Finally, Cantor Fitzgerald assumed coverage on Evommune in a research note on Monday, December 1st. They set an "overweight" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, Evommune has an average rating of "Buy" and an average target price of $39.33.
Get Our Latest Stock Report on EVMN
Evommune Company Profile
(
Get Free Report)
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients' quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
